Key Figures Q4 2022
|
SEK m, unless otherwise stated |
2022 |
2021 |
2022 |
2021 |
% Change |
| Net revenues | 156 | 144 | 624 | 565 | 8.3% |
| Cost of goods sold | -26 | -20 | -103 | -79 | -30.0% |
| Operating expenses | -201 | -188 | -706 | -700 | -6.9% |
| EBIT | -71 | -64 | -184 | -214 | -10.9% |
| EBIT margin, % | -46% | -45% | -30% | -38% | -2.2% |
| EBITDA | -53 | -49 | -115 | -161 | -8.2% |
| Earnings per share, before dilution, SEK | -3 | -2 | -5 | -7 | -50.0% |
| Earnings per share, after dilution, SEK | -3 | -2 | -5 | -7 | -50.0% |
| Cash flow from operating activities | -50 | -81 | -157 | -229 | 38.3% |
| Cash and cash equivalents | 1321 | 504 | 1321 | 504 | -73.8% |
Net revenues and EBIT per segment Q4 2022
|
|
Net Revenues |
EBIT |
||||||
|
|
2022 |
2021 |
2022 |
2021 |
2022 |
2021 |
2022 |
2021 |
| ZUBSOLV® US | 143 | 134 | 571 | 523 | - | - | - | - |
| US Pharma – total | 143 | 134 | 571 | 523 | 77 | 72 | 308 | 278 |
| Digital Therapeutics (DTx) product sales | 0.0 | 0.3 | 0.4 | 1.1 | - | - | - | - |
| Digital Therapeutics (DTx) – total | 0.0 | 0.3 | 0.4 | 1.1 | -49 | -64 | -189 | -250 |
| Abstral® royalties | 6 | 8 | 30 | 32 | - | - | - | - |
| Edluar® royalties | 3 | 2 | 10 | 9 | - | - | - | - |
| ZUBSOLV® - ex US | 5 | - | 12 | - | - | - | - | - |
| HQ & Pipeline - total | 13 | 10 | 53 | 41 | -99 | -73 | -303 | -243 |
| Total | 156 | 144 | 624 | 565 | -71 | -64 | -184 | -214 |
Cash flow Q4 2022
SEK m |
2022 |
2021 |
2022 |
2021 |
| Cash flow from operating activities | -49 | -81 | -157 | -229 |
| Investment activities | 66 | -3 | -235 | -53 |
| Financing activities | -6 | -6 | -21 | 251 |
| Cash flow (excl exchange rate differences) | 12 | -89 | -413 | -31 |
| Liquid funds | 1321 | 504 | 1321 | 504 |
1 Cash and cash equivalents excluding invested surplus cash of SEK 132.2 m in short-term assets, certificates of deposits and in US treasuries. As of December 31, 2022, cash and invested funds amounted to SEK 351.9 m (504.1)